{"url_path":"/sec/trax/8-k/2026-06-22/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/2091349/0001193125-26-277504-index.html","accession_number":"0001193125-26-277504","cik":"0002091349","ticker":"TRAX","issuer_name":"First Tracks Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2091349/0001193125-26-277504-index.html","primary_entity_key":"0002091349","primary_entity_name":"First Tracks Biotherapeutics, Inc."},"word_count":574,"has_tables":true,"body_markdown":"## Item 1.01 Entry into a Material Definitive Agreement.\n\nOn June 15, 2026, First Tracks Biotherapeutics, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with AnaptysBio, Inc., a Delaware corporation (“AnaptysBio”), pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121 (the “Premises”). The Premises are currently leased by AnaptysBio from Wateridge Property Owner, LP, a Delaware limited partnership (the “Master Landlord”), pursuant to the Lease dated May 4, 2020, as amended by the First Amendment to Lease Agreement dated April 5, 2021 (collectively, the “Master Lease”).\n\nThe term of the Sublease commenced on June 15, 2026, and continues for a period of twelve (12) months from commencement (the “Sublease Term”). The Company has the option to extend the Sublease Term for a renewal period commencing on the first day following the expiration of the initial Sublease Term and continuing until the earlier of (a) April 4, 2028, or (b) twelve months from the commencement of the renewal term, subject to delivery of written notice to AnaptysBio at least three months prior to the expiration of the initial Sublease Term. The Company also has the right to terminate the Sublease at any time during the Sublease Term upon at least three months’ prior written notice to AnaptysBio.\n\nUnder the Sublease, the Company is obligated to pay as monthly rent an amount equal to the monthly Basic Rent (as designated in the Master Lease) owed by AnaptysBio under the Master Lease, plus Additional Rent (as defined in the Master Lease) due under the Master Lease, payable in advance on the first day of each month during the Sublease Term. The Company is also responsible for any charges actually incurred for services requested by the Company that AnaptysBio is liable to the Master Landlord for under the Master Lease. AnaptysBio remains responsible for the timely payment of Basic Rent and Additional Rent under the Master Lease and for otherwise complying with its obligations under the Master Lease except to the extent assumed by the Company.\n\nThe Sublease is subordinate to the Master Lease, and the Company has agreed to comply with the applicable terms and provisions of the Master Lease as incorporated into the Sublease.\n\nAnaptysBio has covenanted that it will not surrender or terminate the Master Lease prior to its scheduled expiration date without the consent of the Company (other than in connection with the exercise of its Termination Option (as defined in the Master Lease)), and will not amend or modify the Master Lease in any manner that would materially and adversely affect the Company’s rights or obligations under the Sublease. If AnaptysBio’s tenancy or right to possession under the Master Lease terminates for any reason, the Sublease will immediately cease and terminate.\n\nThe foregoing description of the Sublease does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Sublease, a copy of which will be filed with the Company’s quarterly report on Form 10-Q for the three month period ending June 30, 2026.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nFIRST TRACKS BIOTHERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 22, 2026\n\nBy:\n\n/s/ Ajim Tamboli\n\n \n\n \n\n \n\nName: Ajim Tamboli\nTitle: Chief Financial Officer"}